The immediate goal of the trial was to determine the breast cancer patient tolerance and the toxicity of Laser
immunotherapy (LIT), the optimal dose for the alteration of the course of the disease, and the reduction of
the tumor burden. Ten stage III and IV cancer patients were treated, all of which were considered to be out of
all other options. No toxicity or significant adverse reactions were observed and the treatment was well
tolerated by all patients. Almost all the treated patients have had positive responses: A majority of patients
experienced large-scale reduction of primary breast tumors, and all the stage IV patients experienced either
complete or significant reductions in distant metastases in the lungs, liver, bone, and the brain, indicating a
strong systemic effect of the treatment. We also report two cases of triple negative breast cancer patients that
showed limited or no response to LIT.
|